Form 4: Adicet Bio Director Jeffrey Chodakewitz Receives Significant Equity Compensation

Adicet Bio, Inc. Director Jeffrey Chodakewitz was granted 5,900 Restricted Stock Units and options to purchase 26,400 shares of common stock on June 11, 2025, as part of his compensation.

Summary

• Jeffrey Chodakewitz, a Director of Adicet Bio, Inc. (ACET), reported an acquisition of securities on June 11, 2025.
• The director was granted 5,900 Restricted Stock Units (RSUs) of Common Stock, with each RSU representing a contingent right to receive one share of Common Stock.
• Additionally, options to purchase 26,400 shares of Common Stock were granted, with an exercise price of $0.78 per share.
• Both the RSUs and stock options are set to vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date, contingent upon the director's continued service on the Issuer's board.
• Following these transactions, Jeffrey Chodakewitz beneficially owns 17,700 shares of Common Stock and 26,400 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for aligning management interests with shareholders and retaining talent, but it does not reflect significant operational or financial performance news that would dramatically alter the company's outlook.

Positives

• The grant of equity awards (RSUs and stock options) to Director Jeffrey Chodakewitz aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The compensation structure encourages the director's continued service and commitment to the company's strategic objectives.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the Reporting Person's continued service on the Issuer's board of directors, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The equity awards are structured to vest over the next year or by the next annual meeting, subject to continued service, indicating an expectation of the director's ongoing involvement and commitment to the company's future strategic direction and performance.

Industry Context

The grant of equity awards to directors is a common and standard practice in the biotechnology and pharmaceutical industries. This compensation method serves to align the interests of board members with long-term shareholder value creation, attract and retain experienced leadership, and incentivize performance within a highly competitive sector.

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Jeffrey Chodakewitz, a director of Adicet Bio, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• **Shareholders:** The equity grants align the director's financial interests with long-term shareholder value creation, potentially leading to more focused decision-making and improved governance.
• **Director:** Jeffrey Chodakewitz receives significant equity compensation, incentivizing his continued service and commitment to the company's success.

Next Steps

• The Restricted Stock Units and stock options are scheduled to vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, subject to the director's continued service.

Key Dates

Keywords

Adicet Bio, ACET, SEC Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Director Compensation, Corporate Governance